OPM receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

Dijon, France, March 3, 2026 at 6:30 pm CET – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) Therapeutic Pipeline Program (TPP). The grant aims to prepare OPM’s OPM-201 LRRK2 inhibitor to start its Phase 1b clinical study in 2027 in early people with Parkinson’s disease, with a focus on LRRK2 mutation carriers.